OTCMKTS:HKMPF - Hikma Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$33.00
+0.30 (1.20%)
1 month | 3 months | 12 months
Get New Hikma Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HKMPF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HKMPF

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 6 analysts offering 12 month price targets for Hikma Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $33.00.
Buy
The current consensus among 6 contributing investment analysts is to buy stock in Hikma Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/26/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/24/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/23/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/22/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/20/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/18/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/19/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/18/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetDetails
4/6/2021Morgan StanleyUpgradeEqual Weight ➝ Overweight
i
3/31/2021Jefferies Financial GroupUpgradeHold ➝ Buy
i
3/8/2021BarclaysReiterated RatingOverweight
i
2/26/2021JPMorgan Chase & Co.Reiterated RatingOverweight
i
2/26/2021Morgan StanleyReiterated RatingEqual Weight
i
2/18/2021Morgan StanleyReiterated RatingEqual Weight
i
1/25/2021Peel HuntDowngradeBuy ➝ Hold
i
11/24/2020JPMorgan Chase & Co.Reiterated RatingOverweight
i
9/22/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight
i
9/8/2020The Goldman Sachs GroupUpgradeNeutral ➝ Buy
i
9/4/2020BarclaysUpgradeEqual Weight ➝ Overweight
i
8/14/2020BarclaysReiterated RatingEqual Weight
i
7/7/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight
i
4/28/2020BarclaysReiterated RatingEqual Weight
i
4/23/2020The Goldman Sachs GroupDowngradeBuy ➝ Neutral
i
4/16/2020Jefferies Financial GroupDowngradeBuy ➝ Hold
i
3/10/2020CitigroupUpgradeNeutral ➝ Buy
i
9/3/2019The Goldman Sachs GroupInitiated CoverageBuy
i
3/19/2019CitigroupUpgradeNeutral ➝ Buy
i
11/27/2018Jefferies Financial GroupUpgradeHold ➝ Buy
i
1/10/2018Jefferies Financial GroupDowngradeHold ➝ Underperform
i
8/22/2017The Goldman Sachs GroupDowngradeBuy ➝ Neutral
i
8/21/2017Jefferies Financial GroupUpgradeUnderperform ➝ Hold
i
8/8/2017Morgan StanleyReiterated RatingEqual Weight
i
8/2/2017Morgan StanleyReiterated RatingOverweight ➝ Equal Weight
i
5/19/2017Numis SecuritiesReiterated RatingBuy ➝ Add
i
5/17/2017Jefferies Financial GroupDowngradeBuy ➝ Underperform
i
11/16/2016Morgan StanleyUpgradeEqual Weight ➝ Overweight
i
(Data available from 4/19/2016 forward)
Hikma Pharmaceuticals logo
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment develops, manufactures, and sells generic injectable products primarily for use in hospitals. The Generics segment develops, manufactures, and sells oral and other non-injectable generic products for the retail market. The Branded segment develops, manufactures, markets, and sells branded generics and in-licensed products to retail and hospital markets. The company offers its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, anesthetic, sedative, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.
Read More

Today's Range

Now: $33.00
$33.00
$33.00

50 Day Range

MA: $31.56
$30.15
$33.00

52 Week Range

Now: $33.00
$26.20
$42.00

Volume

410 shs

Average Volume

740 shs

Market Capitalization

$8.00 billion

P/E Ratio

22.00

Dividend Yield

0.48%

Beta

0.41

Frequently Asked Questions

What sell-side analysts currently cover shares of Hikma Pharmaceuticals?

The following equities research analysts have issued research reports on Hikma Pharmaceuticals in the last year: Barclays PLC, Jefferies Financial Group Inc., JPMorgan Chase & Co., Morgan Stanley, Peel Hunt, The Goldman Sachs Group, Inc., and Zacks Investment Research.
View the latest analyst ratings for HKMPF.

What is the current price target for Hikma Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Hikma Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Hikma Pharmaceuticals in the next year.
View the latest price targets for HKMPF.

What is the current consensus analyst rating for Hikma Pharmaceuticals?

Hikma Pharmaceuticals currently has 1 hold rating and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HKMPF will outperform the market and that investors should add to their positions of Hikma Pharmaceuticals.
View the latest ratings for HKMPF.

What other companies compete with Hikma Pharmaceuticals?

How do I contact Hikma Pharmaceuticals' investor relations team?

Hikma Pharmaceuticals' physical mailing address is 1 NEW BURLINGTON PLACE, LONDON X0, W1S 2HR. The company's listed phone number is 44-20-7399-2760 and its investor relations email address is [email protected] The official website for Hikma Pharmaceuticals is www.hikma.com.